{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,23]],"date-time":"2026-09-23T20:29:46Z","timestamp":1790195386981,"version":"4.1.0"},"reference-count":43,"publisher":"Oxford University Press (OUP)","issue":"3","license":[{"start":{"date-parts":[[2026,3,5]],"date-time":"2026-03-05T00:00:00Z","timestamp":1772668800000},"content-version":"vor","delay-in-days":4,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100004191","name":"Novo Nordisk","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100004191","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2026,3,4]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Objective<\/jats:title>\n                    <jats:p>Short stature in children born small for gestational age (SGA) is treated with daily injections of recombinant growth hormone (GH), a significant treatment burden. The objective of this study is to demonstrate the efficacy and safety of once-weekly somapacitan, a long-acting GH, in short children born SGA.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Design<\/jats:title>\n                    <jats:p>REAL8 (NCT05330325) is a multinational, multicenter, randomized, open-labeled, active comparator, phase 3 basket study including four non-GH deficiency indications comprising a 52-week main phase and 104-week extension. Here, we present 52-week results from the SGA sub-study.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>142 prepubertal, treatment-na\u00efve children born SGA in 78 sites across 26 countries were randomized 2:1:1 to somapacitan .24\u2005mg\/kg\/week or daily GH 0.035 or 0.067\u2005mg\/kg\/day, all administered subcutaneously. 140 completed the main 52-week treatment period.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>The primary endpoint, estimated mean height velocity at week 52, was 11.0\u2005cm\/year for somapacitan vs. 9.4\u2005cm\/year [ETD = 1.6(0.91, 2.23)95%CI] and 11.1\u2005cm\/year [ETD = -0.1(\u22120.75, 0.60)95%CI] for daily GH 0.035 and 0.067\u2005mg\/kg\/day, respectively. Noninferiority was confirmed for somapacitan compared to both daily GH groups. Superiority was demonstrated for somapacitan versus daily GH 0.035\u2005mg\/kg\/day. Safety profiles were similar between treatment groups. As expected, somapacitan reduced disease burden at week 52, as for daily GH 0.067\u2005mg\/kg\/day, while somapacitan was associated with reduced treatment burden.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>Somapacitan provides similar efficacy, safety, and tolerability as daily GH in short children born SGA after 52 weeks of treatment. Somapacitan may be an attractive alternative to daily GH in this population, reducing treatment burden to improve adherence and treatment outcomes.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1093\/ejendo\/lvag021","type":"journal-article","created":{"date-parts":[[2026,2,28]],"date-time":"2026-02-28T12:55:39Z","timestamp":1772283339000},"page":"311-325","source":"Crossref","is-referenced-by-count":2,"title":["Somapacitan in children born small for gestational age: a randomized controlled phase 3 trial"],"prefix":"10.1093","volume":"194","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-3455-002X","authenticated-orcid":false,"given":"Agn\u00e8s","family":"Linglart","sequence":"first","affiliation":[{"name":"Universit\u00e9 Paris-Saclay, Inserm, AP-HP, Service d'Endocrinologie et dab\u00e8te de l'enfant, H\u00f4pital Bic\u00eatre Paris Saclay , Le Kremlin-Bic\u00eatre F-94270 ,","place":["France"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Volker","family":"B\u00f6ttcher","sequence":"additional","affiliation":[{"name":"Division of Pediatric Endocrinology and Metabolism, MVZ Endokrinologikum Frankfurt am Main , Frankfurt 60596 ,","place":["Germany"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2210-0366","authenticated-orcid":false,"given":"Michael","family":"H\u00f8jby","sequence":"additional","affiliation":[{"name":"Research & Development, Novo Nordisk A\/S , S\u00f8borg 2860 ,","place":["Denmark"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kamil","family":"Soltysik","sequence":"additional","affiliation":[{"name":"Research & Development, Novo Nordisk A\/S , S\u00f8borg 2860 ,","place":["Denmark"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Carlos Alberto","family":"Longui","sequence":"additional","affiliation":[{"name":"Pediatric Endocrinology Unit, Pediatric Department, Irmandade da Santa Casa de Miseric\u00f3rdia de S\u00e3o Paulo and Santa Casa de Sao Paulo School of Medical Sciences , S\u00e3o Paulo 01221-020 ,","place":["Brazil"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lawrence","family":"Silverman","sequence":"additional","affiliation":[{"name":"Goryeb Children's Hospital, Atlantic Health System , New Jersey 07960 ,","place":["United States"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2505-5932","authenticated-orcid":false,"given":"Kenichi","family":"Kashimada","sequence":"additional","affiliation":[{"name":"Department of Pediatrics and Developmental Biology, Institute of Science Tokyo (IST) , Tokyo 152-8550 ,","place":["Japan"]},{"name":"National Center for Child Health and Development , Tokyo 157-8535 ,","place":["Japan"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2026,3,5]]},"reference":[{"issue":"5","key":"2026033105111832100_lvag021-B1","doi-asserted-by":"publisher","first-page":"372","DOI":"10.1111\/ped.12859","article-title":"Prevalence of small for gestational age (SGA) and short stature in children born SGA who qualify for growth hormone treatment at 3 years of age: population-based study","volume":"58","author":"Fujita","year":"2016","journal-title":"Pediatr Int"},{"key":"2026033105111832100_lvag021-B2","volume-title":"StatPearls [Internet]","author":"Osuchukwu","year":"2021"},{"issue":"1","key":"2026033105111832100_lvag021-B3","doi-asserted-by":"publisher","first-page":"28","DOI":"10.1186\/1475-9276-12-28","article-title":"Contribution of socioeconomic status to the risk of small for gestational age infants\u2013a population-based study of 1,390,165 singleton live births in Finland","volume":"12","author":"R\u00e4is\u00e4nen","year":"2013","journal-title":"Int J Equity Health"},{"issue":"9","key":"2026033105111832100_lvag021-B4","doi-asserted-by":"publisher","first-page":"826","DOI":"10.1136\/jech-2014-205387","article-title":"Mother's education and the risk of preterm and small for gestational age birth: a DRIVERS meta-analysis of 12 European cohorts","volume":"69","author":"Ruiz","year":"2015","journal-title":"J Epidemiol Community Health"},{"issue":"3","key":"2026033105111832100_lvag021-B5","doi-asserted-by":"publisher","first-page":"539","DOI":"10.1210\/endrev\/bnad002","article-title":"International consensus guideline on small for gestational age: etiology and management from infancy to early adulthood","volume":"44","author":"Hokken-Koelega","year":"2023","journal-title":"Endocr Rev"},{"issue":"2","key":"2026033105111832100_lvag021-B6","doi-asserted-by":"publisher","first-page":"267","DOI":"10.1203\/00006450-199508000-00022","article-title":"Children born small for gestational age: do they catch up?","volume":"38","author":"Hokken-Koelega","year":"1995","journal-title":"Pediatr Res"},{"issue":"5","key":"2026033105111832100_lvag021-B7","doi-asserted-by":"publisher","first-page":"1043","DOI":"10.1210\/clinem\/dgac694","article-title":"Early growth hormone initiation leads to favorable long-term growth outcomes in children born small for gestational age","volume":"108","author":"Juul","year":"2023","journal-title":"J Clin Endocrinol Metab"},{"issue":"16","key":"2026033105111832100_lvag021-B8","doi-asserted-by":"publisher","first-page":"1206","DOI":"10.1056\/NEJM199910143411607","article-title":"Growth hormone therapy in adults and children","volume":"341","author":"Vance","year":"1999","journal-title":"N Engl J Med"},{"issue":"4","key":"2026033105111832100_lvag021-B9","doi-asserted-by":"publisher","first-page":"415","DOI":"10.1067\/S0022-3476(03)00246-4","article-title":"Update of guidelines for the use of growth hormone in children: the Lawson Wilkins Paediatric Endocrinology Society Drug and Therapeutics Committee","volume":"143","author":"Lawson Wilkins Paediatric Endocrinology Society","year":"2003","journal-title":"J Pediatr"},{"issue":"3","key":"2026033105111832100_lvag021-B10","doi-asserted-by":"publisher","first-page":"804","DOI":"10.1210\/jc.2006-2017","article-title":"Management of the child born small for gestational age through to adulthood: a consensus statement of the International Societies of Pediatric Endocrinology and the Growth Hormone Research Society","volume":"92","author":"Clayton","year":"2007","journal-title":"J Clin Endocrinol Metab"},{"issue":"4","key":"2026033105111832100_lvag021-B11","doi-asserted-by":"publisher","first-page":"dgz118","DOI":"10.1210\/clinem\/dgz118","article-title":"Increases in bioactive IGF do not parallel increases in total IGF-I during growth hormone treatment of children born SGA","volume":"105","author":"Wegmann","year":"2020","journal-title":"J Clin Endocrinol Metab"},{"issue":"3","key":"2026033105111832100_lvag021-B12","doi-asserted-by":"publisher","first-page":"642","DOI":"10.1210\/clinem\/dgac605","article-title":"Tracking and cumulative lifetime exposure to IGF-I in 6459 healthy individuals and in SGA children treated with GH","volume":"108","author":"Kjaer","year":"2023","journal-title":"J Clin Endocrinol Metab"},{"issue":"1","key":"2026033105111832100_lvag021-B13","doi-asserted-by":"publisher","first-page":"59","DOI":"10.1038\/s41573-022-00529-w","article-title":"Derivatization with fatty acids in peptide and protein drug discovery","volume":"22","author":"Kurtzhals","year":"2023","journal-title":"Nat Rev Drug Discov"},{"issue":"12","key":"2026033105111832100_lvag021-B14","doi-asserted-by":"publisher","first-page":"3378","DOI":"10.1210\/clinem\/dgac513","article-title":"Weekly somapacitan is effective and well tolerated in children with GH deficiency: the randomized phase 3 REAL4 trial","volume":"107","author":"Miller","year":"2022","journal-title":"J Clin Endocrinol Metab"},{"key":"2026033105111832100_lvag021-B15","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1159\/000545786","article-title":"Somapacitan is effective and well tolerated in Chinese children with growth hormone deficiency: a randomised controlled phase 3 study","author":"Fu","year":"2025","journal-title":"Horm Res Paediatr"},{"issue":"4","key":"2026033105111832100_lvag021-B16","doi-asserted-by":"publisher","first-page":"1086","DOI":"10.1210\/clinem\/dgae616","article-title":"Somapacitan in children born SGA: 52-week efficacy, safety, and IGF-I response results from the phase 2 REAL5 study","volume":"110","author":"Juul","year":"2025","journal-title":"J Clin Endocrinol Metab"},{"issue":"1","key":"2026033105111832100_lvag021-B17","doi-asserted-by":"publisher","first-page":"lvac008","DOI":"10.1093\/ejendo\/lvac008","article-title":"Somapacitan in children born small for gestational age: a multi-centre, open-label, controlled phase 2 study","volume":"188","author":"Juul","year":"2023","journal-title":"Eur J Endocrinol"},{"issue":"2","key":"2026033105111832100_lvag021-B18","doi-asserted-by":"publisher","first-page":"63","DOI":"10.1297\/cpe.26.63","article-title":"Evaluation of growth hormone treatment efficacy in short Japanese children born small for gestational age: five-year treatment outcome and impact on puberty","volume":"26","author":"Horikawa","year":"2017","journal-title":"Clin Pediatr Endocrinol"},{"issue":"3","key":"2026033105111832100_lvag021-B19","doi-asserted-by":"publisher","first-page":"170","DOI":"10.1136\/adc.51.3.170","article-title":"Clinical longitudinal standards for height, weight, height velocity, weight velocity, and stages of puberty","volume":"51","author":"Tanner","year":"1976","journal-title":"Arch Dis Child"},{"key":"2026033105111832100_lvag021-B20","first-page":"1","article-title":"CDC growth charts: united States","volume":"314","author":"Kuczmarski","year":"2000","journal-title":"Adv Data"},{"key":"2026033105111832100_lvag021-B21","author":"Centers for Disease Control and Prevention"},{"key":"2026033105111832100_lvag021-B22","first-page":"1","article-title":"Physical growth of Swiss children from birth to 20 years of age: first Zurich longitudinal study of growth and development","volume":"52","author":"Prader","year":"1989","journal-title":"Helv Paediatr Acta Suppl"},{"key":"2026033105111832100_lvag021-B23","volume-title":"Radioagraphic Atlas of Skeletal Development of the Hand and Wrist","author":"Greulich","year":"1973"},{"issue":"9","key":"2026033105111832100_lvag021-B24","doi-asserted-by":"publisher","first-page":"1217","DOI":"10.1007\/s40262-021-01011-3","article-title":"Population pharmacokinetics and pharmacodynamics of once-daily growth hormone Norditropin\u00ae in children and adults","volume":"60","author":"Papathanasiou","year":"2021","journal-title":"Clin Pharmacokinet"},{"issue":"11","key":"2026033105111832100_lvag021-B25","doi-asserted-by":"publisher","first-page":"bvad115","DOI":"10.1210\/jendso\/bvad115","article-title":"Model-based analysis of IGF-I response, dosing, and monitoring for once-weekly somapacitan in children with GH deficiency","volume":"7","author":"Kildemoes","year":"2023","journal-title":"J Endocr Soc"},{"issue":"3","key":"2026033105111832100_lvag021-B26","doi-asserted-by":"publisher","first-page":"988","DOI":"10.1210\/jc.2015-1991","article-title":"Reversible albumin-binding GH possesses a potential once-weekly treatment profile in adult growth hormone deficiency","volume":"101","author":"Rasmussen","year":"2016","journal-title":"J Clin Endocrinol Metab"},{"issue":"26","key":"2026033105111832100_lvag021-B27","doi-asserted-by":"publisher","first-page":"2551","DOI":"10.1056\/NEJMra1817346","article-title":"Pathogenesis and diagnosis of growth hormone deficiency in adults","volume":"380","author":"Melmed","year":"2019","journal-title":"N Engl J Med"},{"issue":"2","key":"2026033105111832100_lvag021-B28","doi-asserted-by":"publisher","first-page":"169","DOI":"10.1111\/j.1365-2265.2012.04420.x","article-title":"Identification and management of poor response to growth-promoting therapy in children with short stature","volume":"77","author":"Bang","year":"2012","journal-title":"Clin Endocrinol (Oxf)"},{"issue":"7235","key":"2026033105111832100_lvag021-B29","doi-asserted-by":"publisher","first-page":"612","DOI":"10.1136\/bmj.320.7235.612","article-title":"Bullying in school: are short pupils at risk? Questionnaire study in a cohort","volume":"320","author":"Voss","year":"2000","journal-title":"BMJ"},{"issue":"6","key":"2026033105111832100_lvag021-B30","doi-asserted-by":"publisher","first-page":"2103","DOI":"10.1210\/jc.2018-02523","article-title":"Improved general and height-specific quality of life in children with short stature after 1 year on growth hormone","volume":"104","author":"Gonz\u00e1lez Brice\u00f1o","year":"2019","journal-title":"J Clin Endocrinol Metab"},{"issue":"3","key":"2026033105111832100_lvag021-B31","doi-asserted-by":"publisher","first-page":"407","DOI":"10.1111\/j.1365-2265.2007.02901.x","article-title":"An evaluation of the relationship between adult height and health-related quality of life in the general UK population","volume":"67","author":"Christensen","year":"2007","journal-title":"Clin Endocrinol (Oxf)"},{"issue":"6","key":"2026033105111832100_lvag021-B32","doi-asserted-by":"publisher","first-page":"C1","DOI":"10.1530\/EJE-16-0111","article-title":"Growth Hormone Research Society perspective on the development of long-acting growth hormone preparations","volume":"174","author":"Christiansen","year":"2016","journal-title":"Eur J Endocrinol"},{"issue":"3","key":"2026033105111832100_lvag021-B33","doi-asserted-by":"publisher","first-page":"261","DOI":"10.1515\/jpem-2022-0359","article-title":"An open-label extension of a phase 2 dose-finding study of once-weekly somatrogon vs. once-daily Genotropin in children with short stature due to growth hormone deficiency: results following 5 years of treatment","volume":"36","author":"Zadik","year":"2023","journal-title":"J Pediatr Endocrinol Metab"},{"issue":"7","key":"2026033105111832100_lvag021-B34","doi-asserted-by":"publisher","first-page":"e2680","DOI":"10.1210\/clinem\/dgac217","article-title":"Safety and efficacy of lonapegsomatropin in children with growth hormone deficiency: enliGHten trial 2-year results","volume":"107","author":"Maniatis","year":"2022","journal-title":"J Clin Endocrinol Metab"},{"issue":"10","key":"2026033105111832100_lvag021-B35","doi-asserted-by":"publisher","first-page":"2569","DOI":"10.1210\/clinem\/dgad183","article-title":"Weekly somapacitan in GH deficiency: 4-year efficacy, safety and treatment\/disease burden results from REAL 3","volume":"108","author":"S\u00e4vendahl","year":"2023","journal-title":"J Clin Endocrinol Metab"},{"issue":"12","key":"2026033105111832100_lvag021-B36","doi-asserted-by":"publisher","first-page":"3090","DOI":"10.1210\/clinem\/dgad394","article-title":"Effective GH replacement with somapacitan in children with GHD: REAL4 2-year results and after switch from daily GH","volume":"108","author":"Miller","year":"2023","journal-title":"J Clin Endocrinol Metab"},{"issue":"5","key":"2026033105111832100_lvag021-B37","doi-asserted-by":"publisher","first-page":"1357","DOI":"10.1210\/clinem\/dgab928","article-title":"Effective GH replacement with once-weekly somapacitan vs daily GH in children with GHD: 3-year results from REAL 3","volume":"107","author":"S\u00e4vendahl","year":"2022","journal-title":"J Clin Endocrinol Metab"},{"issue":"4","key":"2026033105111832100_lvag021-B38","doi-asserted-by":"publisher","first-page":"e1847","DOI":"10.1210\/clinem\/dgz310","article-title":"Once-weekly somapacitan vs daily GH in children with GH deficiency: results from a randomized phase 2 trial","volume":"105","author":"S\u00e4vendahl","year":"2020","journal-title":"J Clin Endocrinol Metab"},{"issue":"4","key":"2026033105111832100_lvag021-B39","doi-asserted-by":"publisher","first-page":"509","DOI":"10.1530\/EJE-14-0419","article-title":"A randomized controlled trial evaluating IGF1 titration in contrast to current GH dosing strategies in children born small for gestational age: the North European small-for-gestational-age study","volume":"171","author":"Jensen","year":"2014","journal-title":"Eur J Endocrinol"},{"key":"2026033105111832100_lvag021-B40","doi-asserted-by":"publisher","first-page":"707","DOI":"10.2147\/PPA.S151736","article-title":"Adherence to antihyperglycemic medications and glucagon-like peptide 1-receptor agonists in type 2 diabetes: clinical consequences and strategies for improvement","volume":"12","author":"Giorgino","year":"2018","journal-title":"Patient Prefer Adherence"},{"issue":"8","key":"2026033105111832100_lvag021-B41","doi-asserted-by":"publisher","first-page":"1813","DOI":"10.1016\/j.clinthera.2015.05.505","article-title":"Systematic literature review and meta-analysis of medication adherence with once-weekly versus once-daily therapy","volume":"37","author":"Iglay","year":"2015","journal-title":"Clin Ther"},{"issue":"7","key":"2026033105111832100_lvag021-B42","doi-asserted-by":"publisher","first-page":"3562","DOI":"10.1007\/s12325-025-03204-9","article-title":"Real-life growth hormone treatment patterns in children from China: a report from two databases","volume":"42","author":"Wu","year":"2025","journal-title":"Adv Ther"},{"key":"2026033105111832100_lvag021-B43","doi-asserted-by":"publisher","first-page":"1617579","DOI":"10.3389\/fped.2025.1617579","article-title":"Adherence to recombinant human growth hormone therapy in children: influencing factors and clinical implications","volume":"13","author":"Chang","year":"2025","journal-title":"Front Pediatr"}],"container-title":["European Journal of Endocrinology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/ejendo\/article-pdf\/194\/3\/311\/67234742\/lvag021.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/ejendo\/article-pdf\/194\/3\/311\/67234742\/lvag021.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,3,31]],"date-time":"2026-03-31T09:11:25Z","timestamp":1774948285000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/ejendo\/article\/194\/3\/311\/8506471"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,3]]},"references-count":43,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2026,3,4]]}},"URL":"https:\/\/doi.org\/10.1093\/ejendo\/lvag021","relation":{},"ISSN":["0804-4643","1479-683X"],"issn-type":[{"value":"0804-4643","type":"print"},{"value":"1479-683X","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2026,3]]},"published":{"date-parts":[[2026,3]]}}}